Use of Roche’s high-speed heart attack test, which “drastically shortens” time to diagnosis and thus facilitates faster treatment and potentially better outcomes, has been validated in a three-year clinical trial involving more than 1,200 patients.
Results from the TRAPID-AMI clinical study, published online by the Annals of Emergency Medicine, confirm that Roche’s troponin T high-sensitivity test reduces the observation time needed to rule-in or rule-out a heart attack from three to six hours to just one hour.
A fast and reliable diagnosis of heart attack is critical for patients because every 30 minutes of delay from the onset of symptoms to treatment increases the mortality risk by 7.5%, Roche notes, highlighting the test’s potential impact.
“Results of the TRAPID-AMI study once again demonstrate how diagnostics can influence clinical practice to contribute to better patient outcomes,” said Roland Diggelmann, Roche Diagnostics’ chief operating officer.
New clinical practice guidelines from The European Society of Cardiology now support the one-hour diagnostic algorithm with high-sensitive troponin testing, as validated by the study.